{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:44:50Z","timestamp":1697237090181},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,10,23]],"date-time":"2007-10-23T00:00:00Z","timestamp":1193097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1038\/ncpendmet0673","type":"journal-article","created":{"date-parts":[[2007,10,23]],"date-time":"2007-10-23T08:32:48Z","timestamp":1193128368000},"page":"20-21","source":"Crossref","is-referenced-by-count":1,"title":["Is yearly intravenous zoledronic acid comparable to weekly oral alendronate for postmenopausal osteoporosis?"],"prefix":"10.1038","volume":"4","author":[{"given":"Maria Luisa","family":"Brandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,23]]},"reference":[{"key":"BFncpendmet0673_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A  et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570\u2013578","journal-title":"Endocr Rev"},{"key":"BFncpendmet0673_CR2","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1210\/jc.2004-2212","volume":"91","author":"D Michalsk\u00e0","year":"2006","unstructured":"Michalsk\u00e0 D  et al. (2006) The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 91: 870\u2013877","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0673_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B  et al. (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745\u2013751","journal-title":"J Bone Miner Res"},{"key":"BFncpendmet0673_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00198-006-0294-8","volume":"18","author":"E Seeman","year":"2007","unstructured":"Seeman E  et al. (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18: 711\u2013719","journal-title":"Osteoporos Int"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0673","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:54:35Z","timestamp":1684439675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,23]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["BFncpendmet0673"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0673","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,23]]}}}